About eli lilly & co. - LLY
LLY At a Glance
| Phone | 1-317-276-2000 | Revenue | 45.04B | |
| Industry | Pharmaceuticals: Major | Net Income | 10.59B | |
| Sector | Health Technology | 2024 Sales Growth | 31.997% | |
| Fiscal Year-end | 12 / 2025 | Employees | 47,000 | |
| View SEC Filings |
LLY Valuation
| P/E Current | 72.765 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 65.905 |
| Price to Sales Ratio | 15.495 |
| Price to Book Ratio | 51.543 |
| Price to Cash Flow Ratio | 79.15 |
| Enterprise Value to EBITDA | 38.722 |
| Enterprise Value to Sales | 16.168 |
| Total Debt to Enterprise Value | 0.046 |
LLY Efficiency
| Revenue/Employee | 958,355.319 |
| Income Per Employee | 225,319.149 |
| Receivables Turnover | 3.393 |
| Total Asset Turnover | 0.631 |
LLY Liquidity
| Current Ratio | 1.154 |
| Quick Ratio | 0.886 |
| Cash Ratio | 0.121 |
LLY Profitability
| Gross Margin | 81.31 |
| Operating Margin | 37.831 |
| Pretax Margin | 28.152 |
| Net Margin | 23.511 |
| Return on Assets | 14.84 |
| Return on Equity | 84.842 |
| Return on Total Capital | 22.138 |
| Return on Invested Capital | 29.494 |
LLY Capital Structure
| Total Debt to Total Equity | 237.063 |
| Total Debt to Total Capital | 70.332 |
| Total Debt to Total Assets | 42.742 |
| Long-Term Debt to Equity | 201.007 |
| Long-Term Debt to Total Capital | 59.635 |
Eli Lilly & Co. in the News
Eli Lilly cuts prices for Zepbound weight-loss drug again
Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.
Running low on Ozempic or another weight loss drug? A new tracker can help
Telehealth company Ro has rolled out a new tool to track the supply of weight loss drugs like Ozempic and Wegovy across the U.S., as patients struggle with shortages.
Nestlé launches food line targeting Ozempic, other weight-loss drug users
Nestlé's new food line, Vital Pursuit, is specifically targeted toward patients using weight-loss medications, which continues to surge in popularity.
25K Americans starting Wegovy weekly as supply increases and prices drop, drugmaker says
Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week.
Meet Disney's newly elected board
Disney CEO Bob Iger will be working closely with his newly elected board, which boasts a handful of current and former Fortune 500 executives and some niche corporate insiders.
Amazon Pharmacy will deliver Eli Lilly's Zepbound, other drugs to customers' doorsteps
Amazon Pharmacy is now a third-party dispensing provider for LillyDirect, the pharmaceutical company's telehealth platform, and gives patients access to more weight-loss drugs.
Experts express concern over pharmaceutical giant Eli Lilly's new website connecting patients to obesity drugs
Eli Lilly, which makes obesity and diabetes drugs like Zepbound and Mounjaro, has launched a new website that connects patients to telehealth services, but the service worries some health experts.
Ozempic, Wegovy and other weight loss drugs present holiday challenges
Holiday prep may include forgoing doses for some people taking medications popularly used to facilitate weight loss. Those who do that need to be careful when resuming them, an expert said.
Eli Lily's Mounjaro is more effective for weight loss than Ozempic, study shows
Mounjaro, which is the brand name for tirzepatide, was shown to be even more powerful than Ozempic in a recent study with adults who were overweight or obese.
Tony Bennett raised Alzheimer's funds, awareness
Musical legend Tony Bennett threw his celebrity behind raising awareness and money for the fight against Alzheimer's after being diagnosed with the crippling disease in 2016.